Gaucher DiseasePhase 3NCT05529992
A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
A Phase 3 study testing Velaglucerase Alfa in people with Gaucher Disease, run by Takeda at 10 sites in China.
Trial summary
The main purpose of this study is to observe the side effects of VPRIV in participants with type 1 Gaucher disease who are either treatment-naïve (newly diagnosed) or who are currently being treated with enzyme replacement therapy (ERT). Read more about this study
- Who is it for?
- Ages 2 years and older
- Conditions the study is for
- Gaucher Disease
- What is being tested?
- Velaglucerase Alfa
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 10 sitesChina
- Study dates
- 3 Jan 2023to 5 Aug 2024
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Has a documented, confirmed diagnosis of type 1 Gaucher disease based on the following, as determined by the investigator:
- Decreased glucocerebrosidase (GCB) activity level that is ≤30% of normal or
- Decreased GCB activity level that is >30% of normal, but with confirmation of genetic mutation test
- Is at least 2 years of age, inclusive, at screening
- Is naive to treatment for Gaucher disease (Has not received treatment for Gaucher disease [investigational or approved products] within the 12 months prior to screening) OR Is receiving or has recently received Imiglucerase ERT (Has received Imiglucerase treatment within the 12 months prior to screening and not within the 14 days prior to screening)
- Has Gaucher disease-related hematological abnormalities, defined as
Show all 11Show fewer
- Hemoglobin levels of ≥1 g/dL below the lower limit of normal for their age and gender AND/OR
- A platelet count of <90 × 10^9/L below the lower limit of normal for their age and gender
- Has Gaucher disease-related viscera abnormalities, defined as the following:
- Participant has at least moderate splenomegaly, assessed by palpation (2 to 3 cm below the left costal margin), or by abdominal radiology scan (magnetic resonance imaging [MRI] or computed tomography [CT] scan, with spleen volume >5 times normal) AND/OR
- Participant has hepatomegaly, assessed by palpation or by abdominal radiology scan (MRI or CT scan); Participants who have undergone splenectomy must have satisfied these criteria for this study.
Who cannot join
- Has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease as assessed by the investigator
- Has had a splenectomy or an active, clinically significant spleen infarction within the 12 months prior to screening
- Has received treatment with any investigational drug or device within 30 days prior to screening, or within 5 half-lives of that investigational product, whichever is greater; such treatment during the study will not be permitted
- Is currently receiving red blood cell growth factor (eg, erythropoietin), chronic systemic corticosteroids, or has been on such treatment within the 6 months prior to screening
- Presents with non-Gaucher disease related exacerbated anemia at screening
- Has experienced a severe (grade 3 or higher) infusion-related hypersensitivity reaction (anaphylactic or anaphylactoid reaction) to any ERT (approved or investigational)
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
China10 sites
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100039
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, 100045
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100730
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510080
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, 510623
Lanzhou University Second Hospital
Lanzhou, Gansu, 730030
Nanjing Children's Hospital
Nanjing, Jiangsu, 210008
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430030
About this study
Official title: A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Velaglucerase Alfa in Chinese Subjects With Type 1 Gaucher Disease
The main purpose of this study is to observe the side effects of VPRIV in participants with type 1 Gaucher disease who are either treatment-naïve (newly diagnosed) or who are currently being treated with enzyme replacement therapy (ERT).
Participants will receive VPRIV intravenously during the treatment period (up to 51 weeks), followed by the end-of-treatment (EOT) visit after 2 weeks.
Read the detailed description
The drug being tested in this study is called Velaglucerase Alfa (VPRIV). VPRIV will be tested to treat participants with type 1 Gaucher disease. This study will look at the safety, efficacy and pharmacokinetics of VPRIV in the treatment of type 1 Gaucher disease.
The study will enroll approximately 20 participants with Gaucher disease. The study comprises a screening period (Day -21 through Day -4), baseline period (Day -3 through Day 0), treatment period (Week 1 to Week 51), and safety follow-up period. Participants will be assigned to the following drug administration:
- Velaglucerase Alfa (VPRIV)
Participants will receive VPRIV as intravenous (IV) infusion every other week from Week 1 through Week 51 during the Treatment Period. Percentage of participants with at least one serious treatment-emergent adverse event (TEAE) will be evaluated throughout the study.
This multi-center trial will be conducted in China. The overall time to participate in this study is approximately 59 weeks. Participants will make a safety follow-up telephone call or visit to the site after 30 (±7) days of the last infusion of the study drug.
- Conditions
- Gaucher Disease
- Being tested
- Velaglucerase Alfa
- Keywords
- VPRIV, Gaucher Disease
- Medical subject headings
- Gaucher Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Velaglucerase AlfaDrug
Also called VPRIV
VPRIV intravenous infusion every other week for 60 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Velaglucerase Alfa (VPRIV) | Experimental | Participants received VPRIV IV infusion at 60 units per kilogram (U/kg) body weight once every other week (EOW) for 60 (+10) minutes for up to 51 weeks. Receives: Drug: Velaglucerase Alfa |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With at Least One Serious Treatment-Emergent Adverse Event (TEAE)
Adverse event(AE)=any untoward medical occurrence in clinical investigation participant administered a drug;it does not necessarily have to have causal relationship with this treatment. AE can therefore be any unfavorable\&unintended sign (example,clinically significant abnormal laboratory value),symptom/disease temporally associated with use of drug whether or not it is considered related to drug. TEAE=any event emerging or manifesting at or after initiation of investigational product or any existing event that worsens in either intensity or frequency following exposure to investigational product. SAE=any untoward clinical manifestation of signs, symptoms, or outcomes(whether considered related to investigational product or not)\&at any dose: results in death,is life-threatening,requires in-patient hospitalization/prolongation of hospitalization,results in persistent/significant disability/incapacity,results in congenital abnormality/birth defect,or is an important medical event.
Measured: Up to 56.2 weeks
Secondary outcomes (22)
Percentage of Participants With TEAEs
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as any event emerging or manifesting at or after the initiation of the investigational product or any existing event that worsens in either intensity or frequency following exposure to the investigational product.
Measured: Up to 56.2 weeks
Percentage of Participants With Infusion-related Reactions Reported as an Adverse Event
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. An infusion-related AE was defined as an AE that 1) began either during or within 12 hours after the start of the infusion and 2) was judged as possibly or probably related to the study treatment.
Measured: Up to 56.2 weeks
Percentage of Participants With Development of Anti-VPRIV Antibodies and Neutralizing Antibodies at Week 53
Percentages were rounded off to the nearest single decimal place.
Measured: Week 53
Number of Participants With Clinically Significant Changes in Laboratory Assessments at Week 53
Clinical laboratory assessments included hematology and serum chemistry. Any clinically significant changes in the clinical laboratory assessment values based on the investigator's interpretation were reported. Only categories with at least one participant with event are presented.
Measured: Week 53
Number of Participants With Abnormal Changes in Laboratory Assessments at Week 53: Urinalysis
Any abnormal changes in the urinalysis assessment values based on the investigator's interpretation were reported. Urinalysis comprised of the following parameters: bilirubin, ketones, glucose, nitrite, occult blood, protein, and urobilinogen.
Measured: Week 53
Number of Participants With at Least One Abnormal Change in an Infusion Vital Sign Parameter at Week 53
Participants with atleast 1 abnormal change (above or below normal) in an infusion vital sign parameter of pulse, temperature, respiratory rate,\& blood pressure were reported. Normal ranges for each vital sign parameter were, pulse (beats per minutes [bpm]): 40-100(≥12 years old), 55-95(≥6 but <12 years old), 65-110(≥2 but <6 years old); body temperature(degree Celsius[˚C]): 36.5 to 37.2(all age groups),respiration rate(breaths/minutes):12-24(≥12 years old),12-22 (≥6 but <12 years old),20-30(≥2 but <6 years old);systolic blood pressure(BP) [millimeters of mercury{mm Hg}]: high: ≥140 (≥18 years old), ≥20+ 80+ 2*age(<18 years old), low: <90 (≥18 years old), < -20+ 80+ 2*age(<18 years old); diastolic BP(mm Hg):high:≥90 (≥18 years old), ≥20+ (80+2*age)*(2/3) (<18 years old) low: <50 (≥18 years old), < -20+ (80+2*age)*(2/3) (<18 years old). As per planned analysis,data was collected in a combined manner for all participants irrespective of age. Only non-zero categories are presented.
Measured: Week 53
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Measurements at Week 53
Participants with clinically significant changes in any ECG measurement, such as PR, QRS, QT, corrected QT intervals, and heart rate based on the investigator's interpretation were reported.
Measured: Week 53
Change From Baseline to Week 53 in Hemoglobin Concentration
Measured: Baseline, Week 53
Change From Baseline to Week 53 in Platelet Count
Measured: Baseline, Week 53
Change From Baseline to Week 53 in Normalized Liver Volume
Normalized liver volume was measured by abdominal magnetic resonance imaging (MRI) or computed tomography (CT) scan. Liver volume was normalized for percent body weight.
Measured: Baseline, Week 53
Change From Baseline to Week 53 in Normalized Spleen Volume
Spleen volume was normalized for percent body weight.
Measured: Baseline, Week 53
Change From Baseline to Week 53 in 36-item Short Form General Health Survey (SF-36) Scores
SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100 for each component summary (i.e., PCS and MCS), where higher scores are associated with less disability and better quality of life.
Measured: Baseline, Week 53
Change From Baseline to Week 53 in Childhood Health Questionnaire-Parent Form 50 (CHQ-PF50) Scores
The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains (global health, physical functioning, role/social limitations (emotional/behavioral and physical), bodily pain/discomfort, behavior, global behavior, mental health, self-esteem, general health perceptions, change in health, parental impact (emotional and time), family activities, and family cohesion) which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A positive change from Baseline indicates improved well-being.
Measured: Baseline, Week 53
Cmax: Maximum Observed Serum Concentration for VPRIV at Week 1
Measured: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
Serum Concentration for VPRIV at Week 37
Measured: Within 3 minutes prior to the end of the 60-minute infusion at Week 37
Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for VPRIV
Measured: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for VPRIV
ng*min/mL denotes nanograms*minutes per milliliter.
Measured: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
Terminal Phase Elimination Half-life (T1/2) for VPRIV
Measured: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
Oral Clearance (CL) for VPRIV
mL/min/kg denotes milliliters per minutes per kilogram.
Measured: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
Apparent Steady-state Volume of Distribution (Vss) for VPRIV
Measured: Pre-dose and at multiple timepoints(up to 120 minutes post-dose on Day 1 of Week 1
Percent Change From Baseline to Week 53 in Biomarker: Plasma Chemokine [C-C Motif] Ligand 18
Measured: Baseline, Week 53
Percent Change From Baseline to Week 53 in Biomarker: Glucopsychosine
Measured: Baseline, Week 53
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Sep 2022
- Study start3 Jan 2023
- Primary completion5 Aug 2024
- Study completion5 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Gaucher DiseaseStudies of the same condition, open and under way.
- More trials run by TakedaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Takeda
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Study Director, Study director, Takeda
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05529992
- Sponsor's protocol ID
- TAK-669-3001
- Other IDs
- 2022-002323-35
- Status last verified
- Jun 2025
- First submitted
- 2 Sep 2022
- Last updated
- 26 Jun 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Velaglucerase Alfa in Chinese Subjects With Type 1 Gaucher Disease
- ClinicalTrials.gov ID
- NCT05529992
- Acronym / sponsor ID
- TAK-669-3001
- Conditions
- Gaucher Disease
- Keywords
- VPRIV, Gaucher Disease
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- TakedaIndustry (pharma, biotech, devices)
- Study start
- 3 Jan 2023 (actual)
- Primary completion
- 5 Aug 2024 (actual)
- Study completion
- 5 Aug 2024 (actual)
- First posted
- 7 Sep 2022 (actual)
- Results
- Posted 26 Feb 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this study is to observe the side effects of VPRIV in participants with type 1 Gaucher disease who are either treatment-naïve (newly diagnosed) or who are currently being treated with enzyme replacement therapy (ERT).
Participants will receive VPRIV intravenously during the treatment period (up to 51 weeks), followed by the end-of-treatment (EOT) visit after 2 weeks.
Detailed description
The drug being tested in this study is called Velaglucerase Alfa (VPRIV). VPRIV will be tested to treat participants with type 1 Gaucher disease. This study will look at the safety, efficacy and pharmacokinetics of VPRIV in the treatment of type 1 Gaucher disease.
The study will enroll approximately 20 participants with Gaucher disease. The study comprises a screening period (Day -21 through Day -4), baseline period (Day -3 through Day 0), treatment period (Week 1 to Week 51), and safety follow-up period. Participants will be assigned to the following drug administration:
- Velaglucerase Alfa (VPRIV)
Participants will receive VPRIV as intravenous (IV) infusion every other week from Week 1 through Week 51 during the Treatment Period. Percentage of participants with at least one serious treatment-emergent adverse event (TEAE) will be evaluated throughout the study.
This multi-center trial will be conducted in China. The overall time to participate in this study is approximately 59 weeks. Participants will make a safety follow-up telephone call or visit to the site after 30 (±7) days of the last infusion of the study drug.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Velaglucerase Alfa (VPRIV) | Experimental | Drug: Velaglucerase AlfaParticipants received VPRIV IV infusion at 60 units per kilogram (U/kg) body weight once every other week (EOW) for 60 (+10) minutes for up to 51 weeks. |
Who may qualify
- Ages
- 2 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (11 listed)
- Has a documented, confirmed diagnosis of type 1 Gaucher disease based on the following, as determined by the investigator:
- Is at least 2 years of age, inclusive, at screening
- Is naive to treatment for Gaucher disease (Has not received treatment for Gaucher disease [investigational or approved products] within the 12 months prior to screening) OR Is receiving or has recently received Imiglucerase ERT (Has received Imiglucerase treatment within the 12 months prior to screening and not within the 14 days prior to screening)
- Has Gaucher disease-related hematological abnormalities, defined as
- Has Gaucher disease-related viscera abnormalities, defined as the following:
Key exclusion criteria (6 listed)
- Has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease as assessed by the investigator
- Has had a splenectomy or an active, clinically significant spleen infarction within the 12 months prior to screening
- Has received treatment with any investigational drug or device within 30 days prior to screening, or within 5 half-lives of that investigational product, whichever is greater; such treatment during the study will not be permitted
- Is currently receiving red blood cell growth factor (eg, erythropoietin), chronic systemic corticosteroids, or has been on such treatment within the 6 months prior to screening
- Presents with non-Gaucher disease related exacerbated anemia at screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Velaglucerase AlfaAlso: VPRIVVPRIV intravenous infusion every other week for 60 minutes. | Drug | Velaglucerase Alfa (VPRIV) |
Primary outcome
Percentage of Participants With at Least One Serious Treatment-Emergent Adverse Event (TEAE)
Time frame: Up to 56.2 weeks
Adverse event(AE)=any untoward medical occurrence in clinical investigation participant administered a drug;it does not necessarily have to have causal relationship with this treatment. AE can therefore be any unfavorable\&unintended sign (example,clinically significant abnormal laboratory value),symptom/disease temporally associated with use of drug whether or not it is considered related to drug. TEAE=any event emerging or manifesting at or after initiation of investigational product or any existing event that worsens in either intensity or frequency following exposure to investigational product. SAE=any untoward clinical manifestation of signs, symptoms, or outcomes(whether considered related to investigational product or not)\&at any dose: results in death,is life-threatening,requires in-patient hospitalization/prolongation of hospitalization,results in persistent/significant disability/incapacity,results in congenital abnormality/birth defect,or is an important medical event.
22 secondary outcomes
Percentage of Participants With TEAEs
Time frame: Up to 56.2 weeks
Percentage of Participants With Infusion-related Reactions Reported as an Adverse Event
Time frame: Up to 56.2 weeks
Percentage of Participants With Development of Anti-VPRIV Antibodies and Neutralizing Antibodies at Week 53
Time frame: Week 53
Number of Participants With Clinically Significant Changes in Laboratory Assessments at Week 53
Time frame: Week 53
Number of Participants With Abnormal Changes in Laboratory Assessments at Week 53: Urinalysis
Time frame: Week 53
Number of Participants With at Least One Abnormal Change in an Infusion Vital Sign Parameter at Week 53
Time frame: Week 53
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Measurements at Week 53
Time frame: Week 53
Change From Baseline to Week 53 in Hemoglobin Concentration
Time frame: Baseline, Week 53
Change From Baseline to Week 53 in Platelet Count
Time frame: Baseline, Week 53
Change From Baseline to Week 53 in Normalized Liver Volume
Time frame: Baseline, Week 53
Change From Baseline to Week 53 in Normalized Spleen Volume
Time frame: Baseline, Week 53
Change From Baseline to Week 53 in 36-item Short Form General Health Survey (SF-36) Scores
Time frame: Baseline, Week 53
Change From Baseline to Week 53 in Childhood Health Questionnaire-Parent Form 50 (CHQ-PF50) Scores
Time frame: Baseline, Week 53
Cmax: Maximum Observed Serum Concentration for VPRIV at Week 1
Time frame: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
Serum Concentration for VPRIV at Week 37
Time frame: Within 3 minutes prior to the end of the 60-minute infusion at Week 37
Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for VPRIV
Time frame: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for VPRIV
Time frame: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
Terminal Phase Elimination Half-life (T1/2) for VPRIV
Time frame: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
Oral Clearance (CL) for VPRIV
Time frame: Pre-dose and at multiple timepoints up to 120 minutes post-dose on Day 1 of Week 1
Apparent Steady-state Volume of Distribution (Vss) for VPRIV
Time frame: Pre-dose and at multiple timepoints(up to 120 minutes post-dose on Day 1 of Week 1
Percent Change From Baseline to Week 53 in Biomarker: Plasma Chemokine [C-C Motif] Ligand 18
Time frame: Baseline, Week 53
Percent Change From Baseline to Week 53 in Biomarker: Glucopsychosine
Time frame: Baseline, Week 53
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- To obtain more information on the study, click here/on this linkLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Related trials for Gaucher Disease
RecruitingObservational study
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders
Neurological Regression, Myoclonus
RecruitingObservational study
Parkinson's Disease in Type 1 Gaucher Disease
Parkinson Disease (PD), Type 1 Gaucher Disease
RecruitingObservational study
Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease
Gaucher Disease Type I, Oxidative Stress
Not yet recruitingPhase 1/2
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
Neuroblastoma
Enrolling by invitationObservational study
Genetic Studies of Lysosomal Storage Disorders
Lysosomal Storage Disorders, Gaucher Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Study Director study director
Takeda
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Velaglucerase Alfa in people with Gaucher Disease, run by Takeda at 10 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 26 Feb 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With at Least One Serious Treatment-Emergent Adverse Event (TEAE) (time frame: Up to 56.2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2025.